203 related articles for article (PubMed ID: 18281677)
1. Bevacizumab plus irinotecan in recurrent glioblastoma.
Chamberlain MC
J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
[No Abstract] [Full Text] [Related]
2. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
Fellah S; Girard N; Chinot O; Cozzone PJ; Callot V
J Clin Oncol; 2011 Apr; 29(11):e308-11. PubMed ID: 21263101
[No Abstract] [Full Text] [Related]
3. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
Gerstner ER; Frosch MP; Batchelor TT
J Clin Oncol; 2010 Feb; 28(6):e91-3. PubMed ID: 19933906
[No Abstract] [Full Text] [Related]
4. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
5. Taming glioblastoma: targeting angiogenesis.
Wong ET; Brem S
J Clin Oncol; 2007 Oct; 25(30):4705-6. PubMed ID: 17947716
[No Abstract] [Full Text] [Related]
6. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Herndon JE; Marcello J; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Wagner M; Bailey L; Bigner DD; Friedman AH; Friedman HS
J Clin Oncol; 2007 Oct; 25(30):4722-9. PubMed ID: 17947719
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
[TBL] [Abstract][Full Text] [Related]
9. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
[TBL] [Abstract][Full Text] [Related]
11. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
[TBL] [Abstract][Full Text] [Related]
12. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T
J Clin Oncol; 2009 Oct; 27(28):4733-40. PubMed ID: 19720927
[TBL] [Abstract][Full Text] [Related]
14. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Kilickap S; Oztoprak I; Yucel B
Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
[No Abstract] [Full Text] [Related]
15. Avastin: more questions than answers. .
Desjardins A; Sampson JH
J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
[No Abstract] [Full Text] [Related]
16. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Chamberlain MC
Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257
[No Abstract] [Full Text] [Related]
17. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Tonder M; Eisele G; Weiss T; Hofer S; Seystahl K; Valavanis A; Stupp R; Weller M; Roth P
Acta Oncol; 2014 Oct; 53(10):1436-40. PubMed ID: 24862539
[No Abstract] [Full Text] [Related]
18. [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
Ringelstein A; Turowski B; Gizewski ER; Schroeteler J; Rapp M; Saleh A; Lanzman RS; Mathys C; Sabel M; Mödder U
Rofo; 2010 Oct; 182(10):868-72. PubMed ID: 20740393
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Kreisl TN; Kim L; Moore K; Duic P; Royce C; Stroud I; Garren N; Mackey M; Butman JA; Camphausen K; Park J; Albert PS; Fine HA
J Clin Oncol; 2009 Feb; 27(5):740-5. PubMed ID: 19114704
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
